Literature DB >> 33554107

Characteristics associated with use of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Burkina Faso, Democratic Republic of Congo, and Uganda.

Philip Anglewicz1, Elizabeth Larson1, Pierre Akilimali2, Georges Guiella3, Patrick Kayembe2, Simon P S Kibira4, Fredrick Makumbi4, Scott Radloff1.   

Abstract

OBJECTIVES: To what extent is DMPA-SC reaching new users versus encouraging method switching among existing users? Though increasingly-popular, little is known about characteristics of women using DMPA-SC in SSA. We compared characteristics of women using DMPA-SC with those of other modern methods, and identified the extent to which women using DMPA-SC switched from another method or are first-time users of contraception. STUDY
DESIGN: We used data collected by the Performance Monitoring for Action (PMA) Project between 2016 and 2019 from three countries, Burkina Faso, Democratic Republic of Congo, and Uganda. We tabulated characteristics of DMPA-SC, DMPA-IM, implant, and male condom users, and used multivariate analysis to compare characteristics of women using DMPA-SC those of the other three methods. We also examined previous contraceptive method use (if any) among women currently using DMPA-SC.
RESULTS: We found that never-married women were more likely to use male condoms instead of DMPA-SC. Women with two or more children (compared to no children or one child) were more likely to use implants instead of DMPA-SC in both Uganda and DRC. DMPA-SC was the first method used by the majority of current users in Burkina Faso and Uganda. DMPA-SC users who previously used another method generally switched from less effective methods.
CONCLUSIONS: Although the characteristics of women using DMPA-SC varied across countries, DMPA-SC appears to be reaching new populations of women instead of inspiring existing modern users to switch to DMPA-SC, and appears to be appealing to first time users of contraception. IMPLICATIONS: It appears that DMPA-SC appeals to new contraceptive users in sub-Saharan Africa, which implies that DMPA-SC may have the potential to increase modern contraceptive prevalence in sub-Saharan African countries.
© 2021 The Authors.

Entities:  

Year:  2021        PMID: 33554107      PMCID: PMC7846921          DOI: 10.1016/j.conx.2021.100055

Source DB:  PubMed          Journal:  Contracept X        ISSN: 2590-1516


  21 in total

1.  Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.

Authors:  Anitra Beasley; Katharine O'Connell White; Serge Cremers; Carolyn Westhoff
Journal:  Contraception       Date:  2014-02-07       Impact factor: 3.375

2.  Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal.

Authors:  Holly M Burke; Monique P Mueller; Brian Perry; Catherine Packer; Leonard Bufumbo; Daouda Mbengue; Ibrahima Mall; Bocar Mamadou Daff; Anthony K Mbonye
Journal:  Contraception       Date:  2014-02-06       Impact factor: 3.375

3.  Provider acceptability of Sayana® Press: results from community health workers and clinic-based providers in Uganda and Senegal.

Authors:  Holly M Burke; Monique P Mueller; Catherine Packer; Brian Perry; Leonard Bufumbo; Daouda Mbengue; Bocar Mamadou Daff; Anthony Mbonye
Journal:  Contraception       Date:  2014-01-21       Impact factor: 3.375

4.  DMPA-SC: an emerging option to increase women's contraceptive choices.

Authors:  Ian Askew; Elisa Wells
Journal:  Contraception       Date:  2018-08-23       Impact factor: 3.375

5.  Use of modern contraception increases when more methods become available: analysis of evidence from 1982-2009.

Authors:  John Ross; John Stover
Journal:  Glob Health Sci Pract       Date:  2013-07-26

6.  Acceptability of the distribution of DMPA-SC by community health workers among acceptors in the rural province of Lualaba in the Democratic Republic of the Congo: a pilot study.

Authors:  Albert Mwembo; Rebecca Emel; Tesky Koba; Jacqueline Bapura Sankoko; Aben Ngay; Rianne Gay; Jane T Bertrand
Journal:  Contraception       Date:  2018-08-14       Impact factor: 3.375

7.  An observational study to test the acceptability and feasibility of using medical and nursing students to instruct clients in DMPA-SC self-injection at the community level in Kinshasa.

Authors:  Jane T Bertrand; Dieudonné Bidashimwa; Paul Bakutuvwidi Makani; Julie H Hernandez; Pierre Akilimali; Arsene Binanga
Journal:  Contraception       Date:  2018-08-16       Impact factor: 3.375

8.  Cost-effectiveness of self-injected DMPA-SC compared with health-worker-injected DMPA-IM in Senegal.

Authors:  Mercy Mvundura; Laura Di Giorgio; Chloe Morozoff; Jane Cover; Marguerite Ndour; Jennifer Kidwell Drake
Journal:  Contracept X       Date:  2019

9.  Rapid Uptake of the Subcutaneous Injectable in Burkina Faso: Evidence From PMA2020 Cross-Sectional Surveys.

Authors:  Guiella Georges; Turke Shani; Coulibaly Hamadou; Scott Radloff; Choi Yoonjoung
Journal:  Glob Health Sci Pract       Date:  2018-03-30

10.  The Coming-of-Age of Subcutaneous Injectable Contraception.

Authors:  Kimberly Cole; Abdulmumin Saad
Journal:  Glob Health Sci Pract       Date:  2018-03-30
View more
  2 in total

1.  DMPA-SC stock: Cross-site trends by facility type.

Authors:  Sophia Magalona; Shannon N Wood; Frederick Makumbi; Funmilola M OlaOlorun; Elizabeth Omoluabi; Akilimali Z Pierre; Georges Guiella; Jane Cover; Philip Anglewicz
Journal:  Contracept X       Date:  2022-04-08

Review 2.  Self-injected contraceptives: does the investment reflect women's preferences?

Authors:  Shannon N Wood; Sophia Magalona; Linnea A Zimmerman; Funmilola OlaOlorun; Elizabeth Omoluabi; Pierre Akilimali; Georges Guiella; Peter Gichangi; Philip Anglewicz
Journal:  BMJ Glob Health       Date:  2022-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.